{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T16:09:08Z","timestamp":1794672548162,"version":"4.9.1"},"reference-count":45,"publisher":"Japanese Society of Internal Medicine","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2016]]},"DOI":"10.2169\/internalmedicine.55.5536","type":"journal-article","created":{"date-parts":[[2016,3,14]],"date-time":"2016-03-14T22:05:23Z","timestamp":1457993123000},"page":"589-595","source":"Crossref","is-referenced-by-count":23,"title":["Presence of Antiphospholipid Antibodies as a Risk Factor for Thrombotic Events in Patients with Connective Tissue Diseases and Idiopathic Thrombocytopenic Purpura"],"prefix":"10.2169","volume":"55","author":[{"given":"Koji","family":"Habe","sequence":"first","affiliation":[{"name":"Department of Dermatology, Mie University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Wada","sequence":"additional","affiliation":[{"name":"Department of Molecular and Laboratory Medicine, Mie University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Blood Transfusion Service, Mie University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohshi","family":"Ohishi","sequence":"additional","affiliation":[{"name":"Blood Transfusion Service, Mie University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Ikejiri","sequence":"additional","affiliation":[{"name":"Central Laboratory, Mie University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimiko","family":"Matsubara","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Mie University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuhiko","family":"Morioka","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Mie University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Kamimoto","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Mie University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoaki","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Mie University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoyuki","family":"Katayama","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Mie University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Mizutani","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Mie University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Palomo IG, Segovia FM, Alarcon ML, et al. An insight into the pathophysiology of thrombosis in antiphospholipid syndrome. Front Biosci 12: 3093-3103, 2007.","DOI":"10.2741\/2297"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Staub HL, Bertolaccini ML, Munther MA. Anti-phosphatidylethanolamine antibody, thromboembolic events and the antiphospholipid syndrome. Autoimmun Rev 52: 804-810, 2012.","DOI":"10.1016\/j.autrev.2012.07.008"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Muscal E, Brey RL. Antiphospholipid syndrome and the brain in pediatric and adult patients. Lupus 19: 406-411, 2010.","DOI":"10.1177\/0961203309360808"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Hughes G. Hughes Syndrome: the antiphospholipid syndrome-a clinical overview. Clin Rev Allergy Immunol 32: 3-12, 2007.","DOI":"10.1007\/BF02686077"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Chandramouli NB, Rodgers GM. Management of thrombosis in women with antiphospholipid syndrome. Clin Obstet Gynecol 44: 36-47, 2001.","DOI":"10.1097\/00003081-200103000-00006"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Ruiz-Irastorza G, Crowther M, Branch W, Khamashta MA. Antiphospholipid syndrome. Lancet 376: 1498-1509, 2010.","DOI":"10.1016\/S0140-6736(10)60709-X"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Ortel TL. Antiphospholipid syndrome: laboratory testing and diagnostic strategies. Am J Hematol 87: S75-S81, 2012.","DOI":"10.1002\/ajh.23196"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Asherson RA, Khamashta MA, Ordi-Ros J, et al. The \"primary\" antiphospholipid syndrome; major clinical and serological features. Medicine 68: 366-374, 1989.","DOI":"10.1097\/00005792-198911000-00004"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Alarcon-Segovia D, Deleze M, Oria CV, Sanchez-Guerrero J, Gomez-Pacheco L. Antiphospholipid antibodies and the antiphospholipid syndrome in SLE. A prospective analysis of 500 consecutive patients. Medicine 68: 353-365, 1989.","DOI":"10.1097\/00005792-198911000-00003"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Avcin T, Silverman ED. Antiphospholipid antibodies in pediatric systemic lupus erythematosus and the antiphospholipid syndrome. Lupus 16: 627-633, 2007.","DOI":"10.1177\/0961203307079036"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Atsumi T, Furukawa S, Amengual O, Koike T. Antiphospholipid antibody associated thrombocytopenia and the paradoxical risk of thrombosis. Lupus 14: 499-504, 2005.","DOI":"10.1191\/0961203305lu2145rr"},{"key":"12","unstructured":"12. Tubach F, Hayem G, Marchand JL, et al. IgG anti-beta2-glycoprotein I antibodies in adult patients with systemic lupus erythematosus: prevalence and diagnostic value for the antiphospholipid syndrome. J Rheumatol 27: 1437-1443, 2000."},{"key":"13","unstructured":"13. Long AA, Ginsberg JS, Brill-Edwards P, et al. The relationship of antiphospholipid antibodies to thromboembolic disease in systemic lupus erythematosus: A cross-sectional study. Thromb Haemost 66: 520-524, 1991."},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Sebastiani GD, Passiu G, Galeazzi M, Porzio F, Carcassi U. Prevalence and clinical associations of anticardiolipin antibodies in systemic lupus erythematosus: a prospective study. Clin Rheumatol 10: 289-293, 1991.","DOI":"10.1007\/BF02208692"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Gupta R, Thabah MM, Gupta S, Shankar S, Kumar A. Clinical significance of antiphospholipid antibodies in Indian scleroderma patients. Rheumatol Int 30: 277-279, 2009.","DOI":"10.1007\/s00296-009-1107-0"},{"key":"16","unstructured":"16. Marie I, Jouen F, Hellot MF, Levesque H. Anticardiolipin and anti-beta2 glycoprotein I antibodies and lupus-like anticoagulant: prevalence and significance in systemic sclerosis. Br J Dermatol 158: 141-144, 2008."},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Pasoto SG, Chakkour HP, Natalino RR, et al. Lupus anticoagulant: a marker for stroke and venous thrombosis in primary Sj&ouml;gren's syndrome. Clin Rheumatol 31: 1331-1338, 2012.","DOI":"10.1007\/s10067-012-2019-z"},{"key":"18","unstructured":"18. Unikiene D, Misiuniene N. Antiphospholipid syndrome in patients with systemic connective tissue diseases. Medicina (Kaunas) 39: 454-459, 2003."},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Olech E, Merrill JT. The prevalence and clinical significance of antiphospholipid antibodies in rheumatoid arthritis. Curr Rheumatol Rep 8: 100-108, 2006.","DOI":"10.1007\/s11926-006-0049-8"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Neville C, Rauch J, Kassis J, et al. Thromboembolic risk in patients with high titre anticardiolipin and multiple antiphospholipid antibodies. Thromb Haemost 90: 108-115, 2003.","DOI":"10.1055\/s-0037-1613606"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Pengo V, Ruffatti A, Legnani C, et al. Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile:a multicenter prospective study. Blood 118: 4714-4718, 2011.","DOI":"10.1182\/blood-2011-03-340232"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Habe K, Wada H, Matsumoto T, et al. Presence of antiphospholipid antibody is a risk factor in thrombotic events in patients with antiphospholipid syndrome or relevant diseases. Int J Hematol 97: 345-350, 2013.","DOI":"10.1007\/s12185-013-1277-0"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Smith EL, Shmerling RH. The American College of Rheumatology criteria for the classification of systemic lupus erythematosus: strengths, weaknesses, and opportunities for improvement. Lupus 8: 586-595, 1999.","DOI":"10.1191\/096120399680411317"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23: 581-590, 1980.","DOI":"10.1002\/art.1780230510"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Rasmussen A, Ice JA, Li H, et al. Comparison of the American-European Consensus Group Sj&ouml;gren's syndrome classification criteria to newly proposed American College of Rheumatology criteria in a large, carefully characterised sicca cohort. Ann Rheum Dis 73: 31-38, 2014.","DOI":"10.1136\/annrheumdis-2013-203845"},{"key":"26","unstructured":"26. George JN, Woolf SH, Raskob GE, et al. Idiopathic thrombocytopenic purpura: a practice guide devel oped by explicit methods for the American Society of Hematology. Blood 88: 3-40, 1996."},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Taylor FB Jr, Toh CH, Hoots WK, Wada H, Levi M. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. On behalf of the Scientific Subcommittee on disseminated intravascular coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH). Thromb Haemost 86: 1327-1330, 2001.","DOI":"10.1055\/s-0037-1616068"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Kaburaki J, Kuwana M, Ikeda Y. Anti-cardiolipin-beta2-GPI complex antibodies in idiopathic thrombocytopenic purpura. Intern Med 37: 796, 1998.","DOI":"10.2169\/internalmedicine.37.796a"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Mu&ntilde;oz-Rodriguez FJ, Font J, Cervera R, et al. Clinical study and follow-up of 100 patients with the antiphospholipid syndrome. Semin Arthritis Rheum 29: 182-190, 1999.","DOI":"10.1016\/S0049-0172(99)80029-8"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Fujieda Y, Atsumi T, Amengual O, et al. Predominant prevalence of arterial thrombosis in Japanese patients with antiphospholipid syndrome. Lupus 21: 1506-1514, 2012.","DOI":"10.1177\/0961203312458469"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Zhou H, Fu R, Wang H, et al. Immune thrombocytopenia in the elderly: clinical course in 525 patients from a single center in China. Ann Hematol 92: 79-87, 2013.","DOI":"10.1007\/s00277-012-1567-2"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome:a systemtic review of the literature. Blood 101: 1827-1832, 2003.","DOI":"10.1182\/blood-2002-02-0441"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Ghosh K, Shetty S, Mohanty D. Detection of unexpected lupus anticoagulant during preparation of normal pooled plasma (NPP) from healthy volunteers. Thromb Haemost 84: 519-521, 2000.","DOI":"10.1055\/s-0037-1614057"},{"key":"34","unstructured":"34. Gris JC, Perneger TV, Qu&eacute;r&eacute; I, et al. Antiphospholipid\/antiprotein antibodies, hemostasis-related autoantibodies, and plasma homocysteine as risk factors for a first early pregnancy loss: a matched case-control study. Blood 102: 3504-3513, 2003."},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Stasi R, Stipa E, Masi M, et al. Prevalence and clinical significance of elevated antiphospholipid antibodies in patients with idiopathic thrombocytopenic purpura. Blood 84: 4203-4208, 1994.","DOI":"10.1182\/blood.V84.12.4203.bloodjournal84124203"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Jennings I, Kitchen S, Kitchen DP, Woods TA, Walker ID. ISTH\/SSC lupus anticoagulant testing guidelines: how far have hese been adopted by laboratories? J Thromb Haemost 9: 2117-2119, 2011.","DOI":"10.1111\/j.1538-7836.2011.04448.x"},{"key":"37","unstructured":"37. Kandiah DA, Krilis SA. Heterogeneity of lupus anticoagulant (LA) antibodies: LA activity in dilute Russell's viper venom time and dilute kaolin clotting time detect different populations of antibodies in patients with the \"antiphospholipid\" syndrome. Thromb Haemost 80: 250-257, 1998."},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Pengo V, Denas G, Bison E, et al; Italian Federation of Thrombosis Centers (FCSA). Prevalence and significance of anti-prothrombin (aPT) antibodies in patients with lupus anticoagulant (LA). Thromb Res 126: 150-153, 2010.","DOI":"10.1016\/j.thromres.2010.05.018"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. De Laat B, Derksen RH, Reber G, et al. An international multicentre-laboratory evaluation of a new assay to detect specifically lupus anticoagulants dependent on the presence of anti-beta2-glycoprotein autoantibodies. J Thromb Haemost 9: 149-153, 2011.","DOI":"10.1111\/j.1538-7836.2010.04068.x"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Pengo V. APS -controversies in diagnosis and management, critical overview of current guidelines. Thromb Res 127: S51-S52, 2011.","DOI":"10.1016\/S0049-3848(11)70014-7"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Deng X, Liu X. Reevaluation of predictive value of ACL and anti-2GP1 antibody for thrombosis in patients with systemic lupus erythematosus: from a perspective of a practical world. Rheumatol Int 32: 3881-3886, 2012.","DOI":"10.1007\/s00296-011-2267-2"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Sciascia S, Murru V, Sanna G, Roccatello D, Khamashta MA, Laura Bertolaccini M. Clinical accuracy for diagnosis of Antiphospholipid Syndrome in SLE: evaluation of 23 possible combinations of antiphospholipid antibody specificities. J Thromb Haemost 10: 2512-2518, 2012.","DOI":"10.1111\/jth.12014"},{"key":"43","unstructured":"43. Nojima J. Advanced clinical laboratory studies in the graduate school of medicine-studies on pathogenic mechanisms of antiphospholipid syndrome. Rinsho Byori (The Japanese Journal of Clinical Pathology) 57: 786-792, 2009 (in Japanese, Abstract in English)."},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Otomo K, Atsumi T, Amengual O, et al. Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events. Arthritis Rheum 64: 504-512, 2012.","DOI":"10.1002\/art.33340"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Horvei LD, Br&aelig;kkan SK, Mathiesen EB, Nj&oslash;lstad I, Wilsgaard T, Hansen JB. Obesity measures and risk of venous thromboembolism and myocardial infarction. Eur J Epidemiol 29: 821-830, 2014.","DOI":"10.1007\/s10654-014-9950-z"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/55\/6\/55_55.5536\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,17]],"date-time":"2020-09-17T04:19:26Z","timestamp":1600316366000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/55\/6\/55_55.5536\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":45,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.55.5536","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016]]}}}